There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicycle Therapeutics (BCYC) and Amag Pharmaceuticals (AMAG) with bullish sentiments.
Bicycle Therapeutics (BCYC)
Bicycle Therapeutics received a Buy rating and a $25.00 price target from H.C. Wainwright analyst Debjit Chattopadhyay today. The company’s shares closed last Thursday at $14.62.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 0.5% and a 38.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics, and Molecular Partners AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bicycle Therapeutics with a $26.17 average price target.
See today’s analyst top recommended stocks >>
Amag Pharmaceuticals (AMAG)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Amag Pharmaceuticals, with a price target of $9.00. The company’s shares closed last Thursday at $6.95.
According to TipRanks.com, Tsao is a 2-star analyst with an average return of 0.0% and a 46.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amag Pharmaceuticals with a $9.33 average price target, representing a 35.4% upside. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
